Skip to main content

Table 6 Main results of the analysis

From: Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study

 

Emergency visits (%)

Hospitalization days

Adverse events (%)

PGx-guided group

B-Mean

11.56

0.39

0.15

B-Stdev

2.98

0.20

0.03

B-Max

23.89

1.42

0.29

B-Min

1.77

0.00

0.04

95%UCI

17.70

0.84

0.22

95%LCI

6.19

0.05

0.09

Control group

B-Mean

13.25

0.88

27.94

B-Stdev

2.97

0.31

3.96

B-Max

25.38

2.13

43.08

B-Min

3.08

0.01

14.62

95%UCI

19.23

1.53

35.38

95%LCI

7.69

0.35

20.00

Control versus PGx-guided

B-Mean

1.69

0.49

12.82

B-Stdev

4.26

0.36

5.23

B-Max

18.00

1.85

30.50

B-Min

− 13.55

− 0.81

− 5.55

95% UCI

10.07

1.23

23.11

95% LCI

− 6.55

− 0.21

2.72

  1. Results were based on 5000 bootstrap experiments
  2. B Bootstrap, LCI Lower Confidence Interval, PGx Pharmacogenomic, SD Standard deviation, UCI Upper confidence interval
Back to article page

Human Genomics

ISSN: 1479-7364